TrialBMC gastroenterology2022

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.

Na Ryung Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.